Pricing Log in Create free account

BioMarin Pharmaceutical Inc. (BMRN) vs Caris Life Sciences,�Inc. (CAI)

BioMarin Pharmaceutical Inc. and Caris Life Sciences,�Inc. are both Biotechnology companies. BioMarin Pharmaceutical Inc. is the larger, with a market value of $11.3B against $9.7B — 1.2× the size. Caris Life Sciences,�Inc. trades at the lower P/E: 86.1× against 151×. Caris Life Sciences,�Inc. grew revenue faster over the last twelve months: 96.4% against 11.2%. Caris Life Sciences,�Inc. has the higher net margin (10.6% vs 2.14%) and the higher return on invested capital (50.0% vs 0.97%). Across the 20 metrics below, Caris Life Sciences,�Inc. leads on 11 and BioMarin Pharmaceutical Inc. on 9.

Valuation

Metric BMRN CAI Biotechnology median
P/E 151.26 86.06 10.71
P/S 3.26 9.25 9.84
P/B 1.76 15.47 2.15
Price to free cash flow 15.34 73.83 25.78
EV/EBITDA 48.52 48.62 0.65
EV/Sales 4.24 8.84 9.47
Earnings yield 0.66% 1.16% (34.53%)
Free cash flow yield 6.52% 1.35% (24.00%)

Profitability

Metric BMRN CAI Biotechnology median
Gross margin 76.12% 69.66% 69.20%
Operating margin 4.38% 15.49% 0.00%
Net margin 2.14% 10.62% 0.00%
Free cash flow margin 21.28% 12.53% 0.00%
Return on equity 1.18% 20.13% (53.10%)
Return on assets 0.76% 9.62% (46.06%)
Return on invested capital 0.97% 49.95% 0.00%

Growth

Metric BMRN CAI Biotechnology median
Revenue growth (TTM) 11.20% 96.36% 5.26%
EPS growth (last fiscal year) (18.55%) 69.79% 29.88%
Revenue growth, 5-year CAGR 11.60% — 9.75%
Net income growth, 5-year CAGR (16.39%) — 0.00%

Health

Metric BMRN CAI Biotechnology median
Debt to equity 0.66 0.66 0.00
Current ratio 2.39 5.53 4.98
Net debt to EBITDA (1.99) (5.23) 1.01

Dividend

Metric BMRN CAI Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric BMRN CAI Biotechnology median
Market cap 11.33b 9.70b 171.46m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack